This book provides readers a fundamental insight into the basic properties of the
pharmaceutical agents used in the treatment of osteoporosis. It provides insight into
mechanisms of action updated information on clinical utility and possible side effects
associated with the use of these pharmaceutical agents. In particular it highlights the use of
two monoclonal antibodies romosozumab and denosumab in activating osteoblast differentiation
and inhibiting osteoclasts. It also discusses two anabolic pharmaceutical agents teriparatide
and abaloparatide to treat osteoporosis. They have been shown to reduce the incidence of
non-vertebral and vertebral fractures significantly after they were administered to patients
daily as subcutaneous injections. The content of this book caters to researchers scientists
and clinical practitioners who are interested in the treatment of osteoporosis using
pharmaceutical agents.
